Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
In a recent transaction disclosed in a Form 4 filing with the Securities and Exchange Commission, Anthony D’Adamio, Senior Vice President and General Counsel at Bioventus Inc. (NASDAQ:BVS), sold 2,958 shares of the company’s Class A common stock. The shares were sold at an average price of $7.57 per share, totaling approximately $22,392. The company, currently valued at $511 million, has seen its stock surge over 71% in the past year, according to InvestingPro data.
This transaction, which took place on April 11, 2025, was conducted under a pre-arranged trading plan adopted on April 10, 2023. The sale was executed to cover tax obligations related to the vesting of restricted stock units. Following this transaction, D’Adamio holds 131,416 shares directly. While the company shows a GOOD financial health score on InvestingPro, analysts have set price targets ranging from $13 to $17, suggesting potential upside from current levels.
The shares were sold as part of a larger trade involving multiple employees of Bioventus, with prices ranging from $7.145 to $7.890. While currently unprofitable, InvestingPro analysis indicates the company is expected to return to profitability this year, with analysts forecasting positive earnings per share of $0.72 for 2025.
In other recent news, Bioventus Inc. reported strong fourth-quarter 2024 earnings, with revenue reaching $154 million, surpassing the expected $145.16 million and marking a 14% year-over-year increase. This performance was driven by robust results in the Surgical Solutions and Pain Treatments segments. The company also reported a full-year adjusted EBITDA of $109 million, reflecting a 23% rise from the previous year. Bioventus paid down nearly $50 million in debt, improving its financial health significantly. Looking ahead to 2025, the company projects net sales between $560 million and $570 million, indicating 6-8% organic growth, and aims for an adjusted EBITDA of $112-$116 million. Canaccord Genuity reaffirmed its Buy rating on Bioventus, maintaining a $15.00 price target, citing the company’s strategic focus and potential for substantial growth under CEO Rob Claypoole. The company continues to focus on expanding its market presence and enhancing profitability, with a commitment to achieving 100 basis points of adjusted EBITDA growth annually.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.